Therapy against reperfusion-induced microvascular injury

Current Pharmaceutical Design

Volumn 19, Issue 25, 2013, Pages 4586-4596

  Tritto, Isabella ^a   Zuchi, Cinzia ^a   Vitale, Serena ^a   Ambrosio, Giuseppe ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Neutrophils; Nitric oxide; No reflow; Reactive oxidant species; Reperfusion injury

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABCIXIMAB; ADENOSINE; ALPHA TOCOPHEROL; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRONEDARONE; ERYTHROPOIETIN; FIBRIN DERIVATIVE; FIBRINOLYTIC AGENT; FX 06; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; NICORANDIL; PEXELIZUMAB; PHOSPHODIESTERASE V INHIBITOR; PHOSPHOLIPASE A2; TIROFIBAN; UNCLASSIFIED DRUG; VERAPAMIL;

ACUTE DRUG ADMINISTRATION; ACUTE HEART INFARCTION; AORTA BALLOON; ARTICLE; BLOOD VESSEL INJURY; CHRONIC DRUG ADMINISTRATION; CORTICOSTEROID THERAPY; COUNTERPULSATION; DRUG MEGADOSE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART PROTECTION; META ANALYSIS (TOPIC); MICROCIRCULATION; NO REFLOW PHENOMENON; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STEM CELL TRANSPLANTATION;

HOMEOSTASIS; HUMANS; MICROVESSELS; MITOCHONDRIA; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; REPERFUSION INJURY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84881359466     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990357     Document Type: Article

References (164)

1. Kloner RA, Ganote CE, Jennings RB. The no-reflow phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54, 1496-1508.
2. Ambrosio G, Weisman HF, Mannisi JA, et al. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation 1989; 80, 1846-61.
3. Rochitte CE, Lima JA, Bluemke DA et al. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation 1998; 98: 1006-14.
4. Galiuto L, Lombardo A, Maseri A, Santoro L, et al. Temporal evolution and functional outcome of no réow: sustained and spontaneously reversible patterns following successful coronary recanalization. Heart 2003; 89: 731-7.
5. Rezkalla SH, Dharmashankar KC, Abdalrahman IB, Kloner RA. No-réow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interv Cardiol 2010; 23: 429-36.
6. Niccoli G, Cosentino N, Lombardo A, et al. Angiographic patterns of myocardial reperfusion after primary angioplasty and ventricular remodeling. Coron Artery Dis 2011; 22: 507-14.
7. Reffelmann T, Kloner RA. The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol 2006; 101: 359-72.
8. Kloner RA, Rude RE, Carlson N, et al. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: Which comes first? Circulation 1980; 6: 945-52.
9. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002; 105: 656-2.
10. Tritto I, Ambrosio G. The multi-faceted behavior of nitric oxide in vascular "inflammation": catchy terminology or true phenomenon? Cardiovasc Res 2004; 63: 1-4.
11. Aversano T, Zhou W, Nedelman M, et al. A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion. J Am Coll Cardiol 1995; 25: 781-812.
12. Ohnishi M, Yamada K, Morooka S, Tojo SJ. Inhibition of Pselectin attenuates neutrophil-mediated myocardial dysfunction in isolated rat heart. Eur J Pharmacol 1999; 366: 271-9.
13. Duilio C, Ambrosio G, Kuppusamy P, et al. Neutrophils are primary source of O2 radicals during reperfusion after prolonged myocardial ischemia. Am J Physiol Heart Circ Physiol 2001; 280: H2649-57
14. Golino P, Ragni M, Cirillo P, et al. Effects of Tissue Factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med 1996; 2: 35-40.
15. Golino P, Ragni M, Cirillo P, et al. Recombinant human, active site-blocked factor VIIa reduces infarct size and no-reflow phenomenon in rabbits. Am J Physiol Heart Circ Physiol 2000; 278: H1507-16
16. Kloner RA, Alker KJ. The effect of streptokinase on intramyocardial hemorrhage, infarct size, and the no-reflow phenomenon during coronary reperfusion. Circulation 1984; 70: 513-21.
17. Sezer M, Oflaz H, Gören T, et al. Intracoronary streptokinase after primary percutaneous coronary intervention. N Engl J Med 2007; 356:1823-34.
18. Kaplanski G, Fabrigoule M, Boulay V, et al Thrombin induces endothelial type II activation in vitro: IL 1 and TNF-alphaindependent IL-8 secretion and E-selectin expression. J Immunol 1997; 158: 5435-41.
19. Yan SF, Tritto I, Pinsky D, et al. Induction of Interleukin-6 (IL-6) by hypoxia in vascular cells: central role of the binding site for nuclear factor-IL-6 (NF-IL-6). J Biol Chem 1995; 270: 11463-72.
20. Shreeniwas R, Koga S, Karakurum M, et al. Hypoxia-mediated induction of endothelial cell interleukin-1. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 1992; 90: 2333-9.
21. Ogawa S, Gerlach H, Esposito C, et al. Hypoxia modulates the barrier and coagulant function of cultured bovine endothelium. Increased monolayer permeability and induction of procoagulant properties. J Clin Invest 1990; 85: 1090-8.
22. Giraldez RR, Panda A, Xia Y, et al. Decreased nitric-oxide synthase activity causes impaired endothelium-dependent relaxation in the postischemic heart. J Biol Chem 1997; 272: 21420-6.
23. Dumitrescu C, Biondi R, Xia Y et al. Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4. Proc Natl Acad Sci U S A. 2007; 104: 15081-6
24. Jones SP, Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 2006; 40: 16-23.
25. Heusch H, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 2008; 118: 1915-9.
26. Lefer DJ, Nakanishi K, Johnston WE, Vinten-Johansen J. Antineutrophil and myocardial protecting actions of a novel nitric oxide donor after acute myocardial ischemia and reperfusion of dogs. Circulation 1993; 88: 2337-50.
27. Rastaldo R, Cappello S, Folino A, et al. Low concentrations of an nitric oxide-donor combined with a liposoluble antioxidant compound enhance protection against reperfusion injury in isolated rat hearts. J Physiol Pharmacol 2010; 61: 21-7.
28. Liu X, Huang Y, Pokreisz P, et al. Nitric oxide inhalation improves microvascular flow and decreases infarction size after myocardial ischemia and reperfusion. J Am Coll Cardiol 2007; 50: 808-17
29. Reffelmann T, Kloner RA. Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation. Cardiovasc Res 2003; 59: 441-9.
30. Salloum FN, Chau VQ, Hoke NN, et al. Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide. Circulation 2009; 120: S31-6
31. Gryglewsky RJ, Palmer RMJ, Moncada S, Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature1986; 320: 454-6.
32. Gasic AC, McGuire G, Krater S, et al. Hydrogen peroxide pretreatment of perfused canine vessels induce ICAM-1 and CD18-dependent neutrophil adherence. Circulation 1991; 84: 2154-66.
33. Lewis MS, Whatley RE, Cain P, et al. Hydrogen peroxide stimulates the synthesis of platelet activating factor by endothelium and induces endothelial cell-dependent neutrophil adhesion, J Clin Invest 1988; 82: 45-55.
34. Ambrosio G, Oriente A, Napoli C, et al. Oxygen radicals inactivate human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor. J Clin Invest 1994; 93: 2408-12.
35. Petrone WF, English DK, Wong K, et al. Free radicals and inflammation: superoxide-dependent activation of a neutrophil chemotactic factor in plasma. Proc Natl Acad Sci U S A 1980; 77: 1159-63.
36. Villari B, Ambrosio G, Golino P, et al. The effects of calcium channel antagonist treatment and oxygen radical scavenging on infarct size and the no-reflow phenomenon in reperfused hearts. Am Heart J 1993; 125:11-23.
37. Cai M, Li Y, Xu Y, et al. Endothelial NOS activity and myocardial oxygen metabolism define the salvageable ischemic time window for ischemic postconditioning. Am J Physiol Heart Circ Physiol 2011; 300: H1069-77.
38. Kotani J, Nanto S, Mintz GS, et al. Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation 2002; 106: 1672-7.
39. Limbruno U, De Carlo M, Pistolesi S, et al: Distal embolization during primary angioplasty: histopathologic features and predictability. Am Heart J 2005; 150: 102-108.
40. Heusch G, Schulz R, Baumgart D, et al. Coronary microembolization. Prog Cardiovasc Dis 2001; 44: 217-30.
41. Skyschally A, Haude M, Dörge H, et al. Glucocorticoid treatment prevents progressive myocardial dysfunction resulting from experimental coronary microembolization. Circulation 2004; 109: 2337-42.
42. Jesel L, Morel O, Ohlmann P et al. Role of pre-infarction angina and inflammatory status in the extent of microvascular obstruction detected by MRI in myocardial infarction patients treated by PCI. Int J Cardiol 2007; 121: 139-47.
43. Niccoli G, Lanza GA, Spaziani C, Crea F. Baseline levels of Creactive protein and no-reflow after primary percutaneous coronary intervention: Int J Cardiol 2007; 17: 306-11
44. Niccoli G, Giubilato, Russo E et al. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur Heart J 2008; 29: 1843-50
45. Zalewski J, Undas A, Godlewski J et al. No-reflow phenomenon after acute myocardial infarction is associated with reduced clot permeability and susceptibility to lysis. Arterioscler Thromb Vasc Biol 2007; 27: 2258-65
46. Niccoli G, Lanza GA, Shaw S et al. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization Eur Heart J 2006; 27: 1793-8
47. Claeys MJ, Bosmans J, Veenstra L, et al. Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: importance of microvascular reperfusion injury on clinical outcome. Circulation 1999; 99: 1972-7.
48. Romano N, Buffoli F, Tomasi L et al. The no-reflow phenomenon in acute myocardial infarction after primary angioplasty: incidence, predictive factors, and long-term outcomes. J Cardiovasc Med (Hagerstown) 2008; 9: 59-63
49. Hong SN, Ahn Y, Hwang SH et al. Usefulness of preprocedural Nterminal pro-brain natriuretic peptide in predicting angiographic no-reflow phenomenon during stent implantation in patients with ST-segment elevation acute myocardial infarction. Am J Cardiol 2007; 100: 631-4.
50. Iwakura K, Ito H, Kawano S, et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol. 2001; 38: 472-7.
51. Colonna P, Cadeddu C, Montisci R et al. Reduced microvascular and myocardial damage in patients with acute myocardial infarction and preinfarction angina. Am Heart J 2002; 144. 796-803.
52. Karila-Cohen D, Czitrom D, Brochett E et al. Decreased no-reflow in patients with anterior myocardial infarction and pre-infarction angina. Eur Heart J 1999; 20. 1724-30.
53. Pagliaro P, Chiribiri A, Mancardi D, et al. Coronary endothelial dysfunction after ischemia and reperfusion and its prevention by ischemic preconditioning. Ital Heart J. 2003; 4: 383-94.
54. Jerome SN, Akimitsu T, Gute DC, Korthuis RJ. Ischemic preconditioning attenuates capillary no-reflow induced by prolonged ischemia and reperfusion. Am J Physiol Heart Circ Physiol 1995; 268: H2063-7.
55. Kusama I, Hibi K, Kosuge M et al. Impact of plaque rupture on infarct size in ST-segment elevation anterior acute myocardial infarction. J Am Coll Cardiol 2007; 50: 1230-37.
56. Lindpaintner K, Jin M, Wilhelm MJ, et al Intracardiac generation of angiotensin and its physiologic role. Circulation 77: I18-I23: 1988.
57. Lindpaintner K, Jin M, Niedermaier N, et al. Cardiac angiotensinogen and its local activation in the isolated perfused beating heart. Circ Res 1990; 67: 564-73.
58. Urata H, Healey B, Stewart RW, et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-90.
59. Gondo M, Maruta H, Arakawa K. Direct formation of angiotensin II without renin or converting enzyme in the ischemic dog heart. Jap Heart J 1989; 30:219-224.
60. Tian R, Neubauer S, Pulzer F, et al. Angiotensin I conversion and coronary constriction by angiotensin II in ischemic and hypoxic isolated rat hearts. Eur J Pharmacol 1991; 203: 71-77.
61. Sweet CS. Issues surrounding a local cardiac renin system and the beneficial actions of angiotensin-converting enzyme inhibitors in ischemic myocardium. Am J Cardiol 1990; 65; 11I-13I.
62. Urata H, Kinoshita A, Misono KS, et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-22357.
63. Petnehazy T, Cooper D, Stokes KY et al. Angiotensin II type 1 receptors and the intestinal microvascular dysfunction induced by ischemia and reperfusion. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1203-10.
64. Focaccio A, Volpe M, Ambrosio G, et al. Angiotensin II directly stimulates release of atrial natriuretic factor in isolated rabbit hearts. Circulation 1993; 87: 192-197
65. Yamamoto Y, Yamamguchi T, Shimamura M, Hazato T. Angiotensin III is a new chemoactractant for polymorphonuclear leukocytes. Biochem Biophys Res Comm 1993; 193: 1038-43.
66. Grafe M, Auch-Schwelk W, Zakrzewicz A, et al. Angiotensin IIinduced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res 1997; 81: 804-11
67. Mikhail EA, Zweier JL, Ambrosio G. Evidence for a role of Angiotensin II on neutrophil-mediated injury in postischemic hearts. J Am Coll Cardiol 1995; February Special Issue: 58A
68. Yusof M, Kamada K, Spencer Gaskin F, Korthuis RJ. Angiotensin II mediates postischemic leukocyte-endothelial interactions: role of calcitonin gene-related peptide. Am J Physiol Heart Circ Physiol 2007; 292: H3032-7.
69. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-35.
70. Dirksen MT, Laarman GJ, Simoons ML, Duncker DJ. Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc Res 2007; 74: 343-55.
71. Schwartz BG, Kloner RA. Coronary no réow. J Mol Cell Cardiol 2012; 52(4): 873-82.
72. Kolodgie FD, Virmani R, Farb A. Limitation of no reflow injury by blood-free reperfusion with oxygenated perfluorochemical (Fluosol-DA 20%). J Am Coll Cardiol 1991; 18: 215-23.
73. Peart JN, Headrick JP. Adenosinergic cardioprotection: multiple receptors, multiple pathways. Pharmacol Ther 2007; 114: 208-21.
74. Galiuto L, DeMaria AN, del Balzo U, et al. Ischemia-reperfusion injury at the microvascular level: treatment by endothelin Aselective antagonist and evaluation by myocardial contrast echocardiography. Circulation 2000; 102: 3111-6.
75. Hale SL, Dae MW, Kloner RA. Hypothermia during reperfusion limits 'no-réow' injury in a rabbit model of acute myocardial infarction. Cardiovasc Res 2003; 59: 715-22.
76. Amado LC, Kraitchman DL, Gerber BL, et al. Reduction of "noreflow" phenomenon by intra-aortic balloon counterpulsation in a randomized magnetic resonance imaging experimental study J Am Coll Cardiol 2004; 43: 1291-8
77. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
78. Ledoux S, Laouari D, Essig M, et al. Lovastatin enhances ecto-5Vnucleotidase activity and cell surface expression in endothelial cells: implication of rho-family GTPases. Circ Res 2002; 90: 420-7.
79. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004-10.
80. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol 1999; 19: 2894-900.
81. Zhao J-L, Yang Y-J, Cui C-J, et al. Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial KATP channel. Br J Pharmacol 2006; 149: 243-9.
82. Yue-Jin Yang, Jing-Lin Zhao, Shi-Jie You, et al. Post-infarction treatment with simvastatin reduces myocardial no-reflow by opening of the KATP channel. Eur J Heart Fail 2007; 9: 30-6.
83. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003; 41: 508-15.
84. Iwakura K, Ito H, Kawano S, et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J. 2006; 27: 534-9.
85. Oduncu V, Tanalp AC, Erkol A, et al. Impact of chronic pretreatment of statins on the level of systemic inammation and myocardial perfusion in patients undergoing primary angioplasty. Am J Cardiol 2011; 107: 179-85.
86. Gibson CM, Morrow DA, Murphy SA, et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol 2006; 47: 2364-73.
87. Zhao JL, Yang YG, You SJ et al. Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Coronary Artery Disease 2006; 17: 463-9
88. Shimizu M, Wang QD, Sjöquist PO, Rydén L. The angiotensin II AT1-receptor antagonist candesartan improves functional recovery and reduces the no-reflow area in reperfused ischemic rat hearts. J Cardiovasc Pharmacol 1999; 34: 78-81.
89. Zhao JL, Yang YJ, Zhang YH, et al. Chronic pretreatment of ACEI reduces no-reflow in patients with acute myocardial infarction treated with primary angioplasty. Clin Cardiol. 2007; 30: 130-4.
90. Micari A, Belcik TA, Balcells EA, et al. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am J Cardiol 2005; 96: 1410-5.
91. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000; 101: 2154-9.
92. Ross AM, Gibbons RJ, Stone GW, et al. A randomized, doubleblinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005; 45: 1775-80.
93. Kloner RA, Forman MB, Gibbons RJ, et al. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 2006; 27: 2400-5.
94. Stoel MG, Marques KM, de Cock CC, et al. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: A randomized placebo-controlled pilot study. Catheter Cardiovasc Interv 2008; 71: 283-9.
95. Grygier M, Araszkiewicz A, Lesiak M, et al. New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 2011; 107: 1131-5.
96. Desmet W, Bogaert J, Dubois C, et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute STsegment elevation myocardial infarction. Eur Heart J 2011; 32: 867-77.
97. Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999; 33: 654-60.
98. Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005; 112: 1284-8.
99. Kitakaze M, Asakura M, Kim J et al.; J-WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomized trials. Lancet 2007; 370: 1483-93.
100. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 30: 1193-9.
101. Amit G, Cafri C, Yaroslavtsev S, et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J 2006; 152: 887. e9-14.
102. Amrani M, Shirvani R, Allen NJ, et al. Enhancement of low coronary reflow improves postischemic myocardial function. J Thorac Cardiovasc Surg 1992; 104: 1375-82
103. Youssef AA, Wu CJ, Hang CL, et al. Impact of PercuSurge device conjugative with intracoronary administration of nitroprusside on no-reflow phenomenon following primary percutaneous coronary intervention. Circ J 2006; 70: 1538-42.
104. Lundberg JO, Gladwin MT, Ahluwalia A, et al. Nitrate and nitrite in biology, nutrition and therapeutics. Nat Chem Biol 2009; 5: 865-9.
105. Kleinbongard P, Böse D, Baars T, et al. Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ Res 2011; 108: 344-52.
106. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary ow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98: 2695-701.
107. Neumann FJ, Zohlnhöfer D, Fakhoury L, et al. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999; 34: 1420-6.
108. Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in STelevation myocardial infarction trial. Circulation 2008; 118: 49-57.
109. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957-66.
110. Kandzari DE, Hasselblad V, Tcheng JE, et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J 2004; 147: 457-62.
111. Van't Hof AW, Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomized controlled trial. Lancet 2008; 372: 537-46.
112. Maioli M, Bellandi F, Leoncini M, et al. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol 2007; 49: 1517-24.
113. Sezer M, Oaz H, Goren T, et al. Intracoronary streptokinase after primary percutaneous coronary intervention. N Engl J Med 2007; 356: 1823-34.
114. Spears JR, Prcevski P, Xu R, et al. Aqueous oxygen attenuation of reperfusion microvascular ischemia in a canine model of myocardial infarction. Asaio J 2003; 49: 716-20.
115. Stone GW, Martin JL, de Boer MJ, et al. Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. Circ Cardiovasc Interv 2009; 2: 366-75.
116. Flaherty JT, Pitt B, Gruber JW, et al Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation. 1994; 89: 1982-91.
117. Heart Protection Study Collaborative. MRC/BHF heart protection study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 23-33.
118. Lonn E, Yusuf S, Hoogwerf B, et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 2002; 25: 1919-27.
119. Zuchi C, Ambrosio G, Lüscher TF, Landmesser U. Nutraceuticals in cardiovascular prevention: lessons from studies on endothelial function. Cardiovasc Ther 2010; 28: 187-201.
120. Miller ER III, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med 2005; 142: 37-46.
121. Mertens P, Maes A, Nuyts J, et al.; PSALM investigators Recombinant P-selectin glycoprotein ligand-immunoglobulin, a P-selectin antagonist, as an adjunct to thrombolysis in acute myocardial infarction. The P-Selectin Antagonist Limiting Myonecrosis (PSALM) trial. Am Heart J 2006; 152: 125. e1-8.
122. Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation. 2001; 104: 2778-83.
123. Faxon DP, Gibbons RJ, Chronos NA, et al. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol 2002; 40: 1199-204.
124. Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003; 108: 1184-90.
125. Chiariello M, Ambrosio G, Cappelli-Bigazzi M, et al. Reduction in infarct size by the phospholipase inhibitor quinacrine in dogs with coronary artery occlusion. Am Heart J 1990; 120: 801-7.
126. Chiariello M, Ambrosio G, Cappelli-Bigazzi M, et al. Inhibition of ischemia-induced phospholipase activation by quinacrine protects jeopardized myocardium in rats with coronary artery occlusion. J Pharmacol Exp Ther 1987; 241: 560-8.
127. Fujioka D, Saito Y, Kobayashi T, et al. Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice. Circulation 2008; 117: 2977-85.
128. Mochly-Rosen D, Grimes KV. Myocardial salvage in acute myocardial infarction-Challenges in clinical translation. J Mol Cell Cardiol 2011; 51: 451-453.
129. Direct Inhibition of delta-Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) Investigators, Bates E, Bode C, Costa M, et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 2008; 117: 886-96.
130. Lincoff AM. Selective inhibition of delta protein kinase C to reduce infarct size after primary percutaneous intervention for acute myocardial infarction: the PROTECTION-AMI Phase IIb Clinical Trial. Am Coll Cardiol 2011 [Epub ahead of print].
131. Atar D, Petzelbauer P, Schwitter J, et al.: F.I.R.E. Investigators. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol 2009; 53: 720-9.
132. Roberts RD, deMello V, Sobel BE. Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation 1976; 53: I204-I6.
133. Scheuer DA, Mifin SW. Chronic corticosterone treatment increases myocardial infarct size in rats with ischemia-reperfusion injury. Am J Physiol Regul Integr Comp Physiol 1997; 272: R2017-24.
134. McSweeney SJ, Hadoke PW, Kozak AM, et al. Improved heart function follows enhanced inflammatory cell recruitment and angiogenesis in 11betaHSD1-deficient mice post-MI. Cardiovasc Res 2010; 88: 159-67.
135. Fraccarollo D, Berger S, Galuppo P, et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 2011; 123: 400-8.
136. Hafezi-Moghadam A, Simoncini T, Yang Z, et al. Acute cardiovascular protective effects of corticosteroids are mediated by nontranscriptional activation of endothelial nitric oxide synthase. Nat Med 2002; 8: 473-9.
137. Skyschally A, Heusch G. Reduction of myocardial infarct size by dronedarone in pigs-a pleiotropic action? Cardiovasc Drugs Ther 2011; 25: 197-201.
138. Heusch G, Skyschally A, Gres P, et al. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine-protection beyond heart rate reduction. Eur Heart J. 2008; 29: 2265-75.
139. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008;103:1204-19.
140. Assmus B, Rolf A, Erbs S, Elsässer A, et al.; REPAIR-AMI Investigators. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail 2010; 3: 89-96.
141. Erbs S, Linke A, Schächinger V, et al. Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial. Circulation 2007; 116: 366-74.
142. Schächinger V, Assmus B, Honold J, et al. Normalization of coronary blood flow in the infarct-related artery after intracoronary progenitor cell therapy: intracoronary Doppler substudy of the TOPCARE-AMI trial. Clin Res Cardiol 2006; 95:13-22.
143. Grajek S, Popiel M, Gil L, Breborowicz P, et al. Influence of bone marrow stem cells on left ventricle perfusion and ejection fraction in patients with acute myocardial infarction of anterior wall: randomized clinical trial: Impact of bone marrow stem cell intracoronary infusion on improvement of microcirculation. Eur Heart J 2010; 31: 691-702.
144. Riksen NP, Hausenloy DJ, Yellon DM. Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci 2008; 29: 258-67.
145. Niccoli G, Andreotti F, Marzo F, et al. Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction. Eur J Clin Invest 2011; 41: 1210-9.
146. Pierrakos CN, Bonios MJ, Drakos SG, et al. Mechanical assistance by intra-aortic balloon pump counterpulsation during reperfusion increases coronary blood flow and mitigates the no-reflow phenomenon: an experimental study. Artif Organs 2011; 35: 867-74.
147. Patel MR, Smalling RW, Thiele H, et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. JAMA 2011; 306: 1329-3.
148. Zhao J, Yang Y, You S, et al. Carvedilol preserves endothelial junctions and reduces myocardial no-réow after acute myocardial infarction and reperfusion. Int J Cardiol 2007; 115: 334-41.
149. Sorrentino SA, Doerries C, Manes C, et al. Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional 1-blockade. J Am Coll Cardiol 2011; 57: 601-1.
150. Yue T.L., Chen J., Bao W., et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferatoractivated receptor-β agonist rosiglitazone. Circulation 2001; 104: 2588-94.
151. Shiomi T, Tsutsui H., Hayashidani S., et al. Pioglitazone, a peroxisome proliferator-activated receptor-β agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 106: 3126-32.
152. Ito H., Nakano A., Kinoshita M., Matsumori A., Pioglitazone, a peroxisome proliferator-activated receptor-β agonist attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest 2003; 83: 1715-21.
153. Honda T, Kaikita K, Tsujita K, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders. J Mol Cell Cardiol 2008; 44: 915-26.
154. Tang L, Zhou SH, Hu XQ, et al. Effect of delayed vs immediate stent implantation on myocardial perfusion and cardiac function in patients with ST-Segment Elevation myocardial infarction undergoing primary percutaneous intervention with thrombus aspiration. Can J Cardiol 2011; 27: 541-7.
155. Jolicoeur EM, Tanguay JF. From primary to secondary percutaneous coronary intervention: the emerging concept of early mechanical reperfusion with delayed facilitated stenting-when earlier may not be better. Can J Cardiol 2011; 27: 529-33.
156. Musiolik J, van Caster P, Skyschally A, et al. Reduction of infarct size by gentle reperfusion without activation of reperfusion injury salvage kinases in pigs. Cardiovasc Res 2010; 85: 110-7.
157. Valgimigli M, Campo G, Malagutti P, et al. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials. JACC Cardiovasc Interv 2011; 4: 51-62.
158. Rentoukas I, Giannopoulos G, Kaoukis A, et al. Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action. JACC Cardiovasc Interv 2010; 3: 49-55.
159. Ambrosio G, Del Pinto M, Tritto I, et al.; GRACE Investigators Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52,693 patients in the Global Registry of Acute Coronary Events. Eur Heart J 2010; 31: 430-8.
160. Kleinbongard P, Schulz R, Heusch G. TNFα in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail Rev. 2011; 16:49-69.
161. De Luca G, Suryapranata H, Stone GW, et al: Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: a meta-analysis of randomized trials. Am Heart J 2007; 153: 343-53.
162. De Luca G, Suryapranata H, Marino P. Reperfusion strategies in acute ST-elevation myocardial infarction: an overview of current status. Prog Cardiovasc Dis 2008; 50: 352-82.
163. Kunichika H, Ben-Yehuda O, Lafitte S et al. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. J Am Coll Cardiol 2004; 43: 276-83.
164. S Baldus, V Rudolph, M Roiss, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 2006; 113: 1871-1878.